Array-based resequencing for mutations causing familial hypercholesterolemia

Kuan Rau Chiou, Min Ji Charng, Hua Mei Chang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Familial hypercholesterolemia (FH) is a heterogeneous autosomal dominant disease with a prevalence of 1 in 500. To date, over 1200 unique pathogenic mutations have been identified in at least 3 genes. The large allelic and genetic heterogeneity of FH requires high-throughput, rapid, and affordable mutation detection technology to efficiently integrate molecular screening into clinical practice. We developed an array-based resequencing assay to facilitate genetic testing in FH patients. Methods and results: We designed a custom DNA resequencing array to detect mutations on all 3 FH-causing genes - LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 gene (PCSK9) - and 290 known insertion/deletion mutations on LDLR. We verified FH array performance by analyzing 35 previously sequenced subjects (21 with point mutations, 2 insertions, 7 deletions, and 5 healthy controls) and blindly screening 125 FH patients. The average microarray call rate was 98.45% and the agreement between microarray and capillary sequencing was 99.99%. The FH array detected mutations by using automated software analysis, followed by manual review in 28 of the 30 subjects (pickup rate, 93.3%). In the blinded study, the FH array detected at least 1 mutation in 77.5% of patients clinically diagnosed with definite FH according to Simon Broome FH criteria and in 52.9% with probable FH diagnosis. Conclusions: The high-throughput FH resequencing array detects LDLR, APOB, and PCSK9 with high efficiency and accuracy and identifies disease-causing mutations. Thus, it facilitates large-scale screening of the heterogeneous FH populations.

Original languageEnglish
Pages (from-to)383-389
Number of pages7
JournalAtherosclerosis
Volume216
Issue number2
DOIs
Publication statusPublished - Jun 1 2011
Externally publishedYes

Fingerprint

Hyperlipoproteinemia Type II
Mutation
LDL Receptors
Apolipoproteins B
Genes
INDEL Mutation
Genetic Heterogeneity
Genetic Testing
Oligonucleotide Array Sequence Analysis
Point Mutation

Keywords

  • Array
  • Familial defective apolipoprotein B
  • Familial hypercholesterolemia
  • Resequence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Array-based resequencing for mutations causing familial hypercholesterolemia. / Chiou, Kuan Rau; Charng, Min Ji; Chang, Hua Mei.

In: Atherosclerosis, Vol. 216, No. 2, 01.06.2011, p. 383-389.

Research output: Contribution to journalArticle

Chiou, Kuan Rau ; Charng, Min Ji ; Chang, Hua Mei. / Array-based resequencing for mutations causing familial hypercholesterolemia. In: Atherosclerosis. 2011 ; Vol. 216, No. 2. pp. 383-389.
@article{df7e5b5667b94c10a12e4a716952f7f5,
title = "Array-based resequencing for mutations causing familial hypercholesterolemia",
abstract = "Background: Familial hypercholesterolemia (FH) is a heterogeneous autosomal dominant disease with a prevalence of 1 in 500. To date, over 1200 unique pathogenic mutations have been identified in at least 3 genes. The large allelic and genetic heterogeneity of FH requires high-throughput, rapid, and affordable mutation detection technology to efficiently integrate molecular screening into clinical practice. We developed an array-based resequencing assay to facilitate genetic testing in FH patients. Methods and results: We designed a custom DNA resequencing array to detect mutations on all 3 FH-causing genes - LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 gene (PCSK9) - and 290 known insertion/deletion mutations on LDLR. We verified FH array performance by analyzing 35 previously sequenced subjects (21 with point mutations, 2 insertions, 7 deletions, and 5 healthy controls) and blindly screening 125 FH patients. The average microarray call rate was 98.45{\%} and the agreement between microarray and capillary sequencing was 99.99{\%}. The FH array detected mutations by using automated software analysis, followed by manual review in 28 of the 30 subjects (pickup rate, 93.3{\%}). In the blinded study, the FH array detected at least 1 mutation in 77.5{\%} of patients clinically diagnosed with definite FH according to Simon Broome FH criteria and in 52.9{\%} with probable FH diagnosis. Conclusions: The high-throughput FH resequencing array detects LDLR, APOB, and PCSK9 with high efficiency and accuracy and identifies disease-causing mutations. Thus, it facilitates large-scale screening of the heterogeneous FH populations.",
keywords = "Array, Familial defective apolipoprotein B, Familial hypercholesterolemia, Resequence",
author = "Chiou, {Kuan Rau} and Charng, {Min Ji} and Chang, {Hua Mei}",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.atherosclerosis.2011.02.006",
language = "English",
volume = "216",
pages = "383--389",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Array-based resequencing for mutations causing familial hypercholesterolemia

AU - Chiou, Kuan Rau

AU - Charng, Min Ji

AU - Chang, Hua Mei

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background: Familial hypercholesterolemia (FH) is a heterogeneous autosomal dominant disease with a prevalence of 1 in 500. To date, over 1200 unique pathogenic mutations have been identified in at least 3 genes. The large allelic and genetic heterogeneity of FH requires high-throughput, rapid, and affordable mutation detection technology to efficiently integrate molecular screening into clinical practice. We developed an array-based resequencing assay to facilitate genetic testing in FH patients. Methods and results: We designed a custom DNA resequencing array to detect mutations on all 3 FH-causing genes - LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 gene (PCSK9) - and 290 known insertion/deletion mutations on LDLR. We verified FH array performance by analyzing 35 previously sequenced subjects (21 with point mutations, 2 insertions, 7 deletions, and 5 healthy controls) and blindly screening 125 FH patients. The average microarray call rate was 98.45% and the agreement between microarray and capillary sequencing was 99.99%. The FH array detected mutations by using automated software analysis, followed by manual review in 28 of the 30 subjects (pickup rate, 93.3%). In the blinded study, the FH array detected at least 1 mutation in 77.5% of patients clinically diagnosed with definite FH according to Simon Broome FH criteria and in 52.9% with probable FH diagnosis. Conclusions: The high-throughput FH resequencing array detects LDLR, APOB, and PCSK9 with high efficiency and accuracy and identifies disease-causing mutations. Thus, it facilitates large-scale screening of the heterogeneous FH populations.

AB - Background: Familial hypercholesterolemia (FH) is a heterogeneous autosomal dominant disease with a prevalence of 1 in 500. To date, over 1200 unique pathogenic mutations have been identified in at least 3 genes. The large allelic and genetic heterogeneity of FH requires high-throughput, rapid, and affordable mutation detection technology to efficiently integrate molecular screening into clinical practice. We developed an array-based resequencing assay to facilitate genetic testing in FH patients. Methods and results: We designed a custom DNA resequencing array to detect mutations on all 3 FH-causing genes - LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 gene (PCSK9) - and 290 known insertion/deletion mutations on LDLR. We verified FH array performance by analyzing 35 previously sequenced subjects (21 with point mutations, 2 insertions, 7 deletions, and 5 healthy controls) and blindly screening 125 FH patients. The average microarray call rate was 98.45% and the agreement between microarray and capillary sequencing was 99.99%. The FH array detected mutations by using automated software analysis, followed by manual review in 28 of the 30 subjects (pickup rate, 93.3%). In the blinded study, the FH array detected at least 1 mutation in 77.5% of patients clinically diagnosed with definite FH according to Simon Broome FH criteria and in 52.9% with probable FH diagnosis. Conclusions: The high-throughput FH resequencing array detects LDLR, APOB, and PCSK9 with high efficiency and accuracy and identifies disease-causing mutations. Thus, it facilitates large-scale screening of the heterogeneous FH populations.

KW - Array

KW - Familial defective apolipoprotein B

KW - Familial hypercholesterolemia

KW - Resequence

UR - http://www.scopus.com/inward/record.url?scp=79957977001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957977001&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2011.02.006

DO - 10.1016/j.atherosclerosis.2011.02.006

M3 - Article

VL - 216

SP - 383

EP - 389

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -